[PDF][PDF] Potential conflicts of interest. The au
HJ de Grooth, JJ Parienti - Lancet Infect Dis, 2024 - scholar.archive.org
1. Parienti JJ, de Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Ethical concern regarding the UK PANORAMIC COVID‐19 trial
R Dal‐Ré, S Holm - British Journal of Clinical Pharmacology, 2022 - ncbi.nlm.nih.gov
PANORAMIC is an open-label, multi-center, randomized, platform, adaptive, controlled trial,
aiming to assess novel SARS-CoV-2 antivirals in the community. 1 This trial, funded by the …
aiming to assess novel SARS-CoV-2 antivirals in the community. 1 This trial, funded by the …
[HTML][HTML] Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13,694 patients
J Lawrence, M Mirchandani, A Hill - 2022 - europepmc.org
Methods Searches of the Clinical Trials Registry-India (CTRI) were conducted to find
registered trials of molnupiravir in India. Subsequent investigations were performed to …
registered trials of molnupiravir in India. Subsequent investigations were performed to …
514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
AA Butt, P Yan, O Shaikh - Open Forum Infectious Diseases, 2023 - academic.oup.com
Background In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
Covid-19: Antiviral purchased by UK government does not lower risk of hospital admission, trial shows
J Wise - BMJ: British Medical Journal (Online), 2022 - search.proquest.com
Abstract Recovery times The Panoramic study, sponsored by the University of Oxford, found
that 0.8% of patients in the molnupiravir group (103 of 12 516) and 0.8% in the usual care …
that 0.8% of patients in the molnupiravir group (103 of 12 516) and 0.8% in the usual care …
[HTML][HTML] Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data
Ever since the emergence of the SARS-CoV-2 pandemic, the quest for efficacious
therapeutic interventions has become a focal point of international health research, focusing …
therapeutic interventions has become a focal point of international health research, focusing …
[引用][C] Surrogate endpoints in pandemic preparedness
HJ de Grooth, JJ Parienti - The Journal of Infectious Diseases, 2024 - academic.oup.com
1. Parienti JJ, de Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
Will Molnupiravir be the First Oral Treatment for High-Risk Non-Hospitalized Patients with Mild-Moderate COVID-19?
S Rao, M Singh - DHR Proceedings, 2021 - dhrproceedings.org
The first case of SARS-CoV-2 infection in United States was confirmed on January 19, 2020,
in a man who had returned home to Snohomish County, Washington on January 15, 2020 …
in a man who had returned home to Snohomish County, Washington on January 15, 2020 …
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …